Who are Recombinant GM-CSF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gm-Csf, Interleukin 2, IL-2 (interleukin 2), Early receiving G-CSF group, vunakizumab and recaticimab., Interferon-Alpha.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-gm-csf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Recombinant GM-CSF — Competitive Intelligence Brief

Recombinant GM-CSF (Recombinant GM-CSF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine; Colony-stimulating factor. Area: Oncology; Immunology.

phase 3 Cytokine; Colony-stimulating factor GM-CSF receptor (CD116/CD131) Oncology; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant GM-CSF (Recombinant GM-CSF) — University of Arkansas. Recombinant GM-CSF stimulates the production and activation of granulocytes and macrophages to enhance immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant GM-CSF TARGET	Recombinant GM-CSF	University of Arkansas	phase 3	Cytokine; Colony-stimulating factor	GM-CSF receptor (CD116/CD131)
Gm-Csf	gm-csf	Pfizer	marketed	cytokine	GM-CSF receptor	1991-01-01
Interleukin 2	Interleukin 2	Assistance Publique - Hôpitaux de Paris	marketed	Cytokine immunotherapy	IL-2 receptor (CD25)
IL-2 (interleukin 2)	IL-2 (interleukin 2)	King's College London	marketed	Cytokine	IL-2 receptor (IL-2R)
Early receiving G-CSF group	Early receiving G-CSF group	Department of Medical Services Ministry of Public Health of Thailand	marketed	Cytokine; Hematopoietic growth factor	G-CSF receptor (GCSFR)
vunakizumab and recaticimab.	vunakizumab and recaticimab.	Xiangya Hospital of Central South University	marketed	Monoclonal antibody (anti-cytokine)	IL-12/IL-23 p40 subunit (vunakizumab); TNF-α (recaticimab)
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine; Colony-stimulating factor class)

University of Arkansas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant GM-CSF — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-gm-csf. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab